18 July 2024 - Voquenza met its primary endpoint in its Phase 3 pivotal trial by demonstrating a significant and rapid reduction of heartburn with daily treatment.
Phathom Pharmaceuticals announced today the US FDA has approved Voquenza (vonoprazan) 10 mg tablets for the relief of heartburn associated with non-erosive gastro-esophageal reflux disease in adults.